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A prognostic factor is one which determines or is related to
the natural history of a disease, in the absence of disease-
modifying therapy. A literature search provides innumerable
studies purporting to describe such factors prognostic for pa-
tients with lung cancer. The potential significance of virtually
every conceivable histopathological feature and molecular
biomarker has been reported in thousands of studies. Yet in
clinical practice, the only prognostic features which are regu-
larly used in clinical decision-making are the tumour stage
and the patient’s performance status. This paper will address
prognostic factors which are features of the tumour, relating
to surgically resected lung cancer. It will not discuss those
features of the individual patient which have prognostic sig-
nificance related to the outcome.
The potential value of efficient prognostication in this par-
ticular clinical setting is to enable appropriate selection of pa-
tients for adjuvant therapy, determining who should benefit
from systemic therapy, with that benefit likely to outweigh
potential toxicity. To a lesser extent, knowledge of a prognos-
tic factor before surgery may influence the type or extent of
surgery which is carried out, but related practice change is
still under trial. Adjuvant treatment is aimed at eliminating
clinically undetectable micro-metastatic disease which, if
present, may be responsible for tumour relapse. Prognostic
factors are therefore predictors of a higher or lower probabil-
ity of disease relapse and indicators of the likelihood that the
surgery alone has cured the patient. Adjuvant therapy is
therefore speculative.
Currently, adjuvant cytotoxic chemotherapy is offered to
patients with pathological Stage II–III non-small-cell lung car-
cinoma (NSCLC) and reduces the risk of death by approxi-
mately 20% [1]. Trials have demonstrated that surgery
effectively cures 64% of patients with p-Stage 1B disease
and 39% and 26% respectively of patients with p-Stage II
and III disease. Only an additional 3% of p-Stage 1B patients,
and 10%/13% respectively of p-Stage II/III patients, will be
alive as a result of adjuvant chemotherapy. Adjuvant chemo-
therapy in p-Stage 1B patients cannot be justified by thismodest gain in survival [1–3]. Despite adjuvant chemother-
apy, 33% of p-Stage IB, 51% of p-Stage II and 61% of p-Stage
III patients succumb to recurrent disease.
The implication of these figures is that current decision-
making should be improved to optimise whom and how to
treat in the adjuvant setting. Prognostic factors that predict
more accurately for postoperative disease relapse could im-
prove selection of those patients most likely to benefit from
adjuvant chemotherapy and – equally importantly – where
it should be avoided. Factors that predict for effectiveness of
individual drugs, which are outside the scope of this review,
could be used to decide how to select chemotherapy for those
who need adjuvant treatment.
1.1. Tumour stage
Tumour stage, a description of the extent of disease, is the
only tumour-related prognostic factor regularly used to in-
form treatment decisions in patients with lung cancer. The
latest iteration of the TNM (tumour, nodes and metastasis)
system, the 7th edition, is the culmination of over 80 years
of historical development and over 10 years of focused project
work by the International Association for the Study of Lung
Cancer (IASLC) [4]. This work is a ‘tour de force’ that evaluates
a large amount of emerging data, changes in imaging, thera-
peutic approach and tumour biology, and conflicts between
the need for retrospective compatibility with earlier systems
and the requirement for better separation of prognostically
divergent groups. The project involved analysis of more than
80,000 resected lung cancers, over 68,000 of which were
NSCLCs. It amalgamated many international databases, but
over half of the cases originated from Europe. Rigorous statis-
tical analysis was applied to the database to produce robust
data for all lung cancers, including evidence to support use
of the TNM staging system in bronchopulmonary carcinoid
tumours and small-cell lung cancer [5–12].
In contrast with the TNM 6th edition, the new TNM 7th
edition shows better separation of the Kaplan–Meier survival
curves for both clinical and pathological staging [8]. The main
changes are (a) the introduction of additional cut-offs of
Table 1 – Median and five-year survivals (5YS) by stage in resected non-small-cell lung cancer under TNM7 [8].
Stage Clinical staging (cStage) Pathological staging (pStage)
Median survival (months) Five-year survival (%) Median survival (months) Five-year survival (%)
IA 60 50 119 73
IB 43 43 81 58
IIA 34 36 49 46
IIB 18 25 31 36
IIIA 14 19 22 24
IIIB 10 7 13 9
IV 6 2 17 13
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>7 cm in diameter from T2 into the T3 category, (c) change
in the way additional pulmonary nodules influence T/M sta-
tus, generally recognising that this is of lesser danger to the
patient than previously thought, (d) reclassification of pleural
effusion as an M descriptor and (e) reassignment of some
T&N combinations to different stages (Table 1). The previ-
ously recognised differences in prognosis related to tumour
stage are clarified, with 5-year survival ranging from 73% in
resected pathological stage IA disease to around 10% for stage
IIIB/IV disease.
It is clear that pathological assessment of tumour stage in
the surgically resected case is at least equally important as is
full histological typing of the tumour [12] (see below). In order
to facilitate an accurate assessment of a submitted specimen,
there is an onus upon the surgeon to communicate all rele-
vant information to the pathologist. Important factors in-
clude anatomical labelling of all specimens, especially
lymph-node samples; details of surgery performed, especially
if non-standard surgery has been performed, to help assist
the assessment of margins; and information regarding any
neo-adjuvant therapy delivered. There is also a duty for the
pathologist to prepare properly the specimens in advance of
dissection, examination and block-taking since these latter
steps are key to determining adequate histological examina-
tion and pathological staging. Inflation fixation of resected
lung bearing tumour is, in the authors’ view, a critical step
in preparation. Usually this involves per-bronchial instillation
of 10% neutral buffered formalin until the lobe or lung is fully
inflated with a smooth pleura. Sub-lobar resections may be
inflated by injection. Although some pathologists prefer sec-
tioning down the bronchi, especially for central bronchial tu-
mours, parasagittal sectioning (the authors’ preference) or
coronal sections give a better view of the parenchyma, and
facilitates both examination of peripheral tumours and corre-
lation with radiology.
1.2. Pathological assessment of lymph nodes
It is clearly important to assess intrapulmonary, hilar and
mediastinal lymph nodes submitted by the surgeon at the
time of lung resection for primary carcinoma, since nodal sta-
tus is a crucial factor in pathological staging. There is, how-
ever, debate in the surgical literature regarding how to deal
with the mediastinal nodes at thoracotomy, with inspection,
node sampling or radical dissection of all tissues at each sta-
tion location being the three widely different options [13]. Im-proved staging, better local disease control and improved
disease-free survival from more extensive surgery must be
set against longer operation times, increased morbidity and
no proven overall survival benefit. The concept of sentinel
node sampling, a procedure common in the surgical manage-
ment of other tumour sites, is poorly developed in the lung
[14]. The European Society of Thoracic Surgeons guidelines
recommend systematic nodal dissection, to include at least
three N1 nodes (inter-lobal and hilar) and three nodes from
three stations, including the sub-carinal station, in the medi-
astinum [15]. There is evidence that the number of lymph
nodes resected, the number that is positive for tumour and
the percentage of resected nodes which are positive have an
influence on postoperative outcome [16–18]. Greater clarity
is required around these data and the significance of the
number of positive lymph node stations, given that true sin-
gle-stationmediastinal lymph-nodemetastases seem to carry
a more favourable prognosis [19,20]. There are practical diffi-
culties relating to assessing lymph node number if nodal frag-
ments rather than whole nodes are delivered to pathology.
There is also evidence that inadequate pathological examina-
tion may underestimate the degree of nodal involvement
[21,22].
Does the degree of nodal involvement matter? Although it
is traditionally taught that extracapsular spread of tumour
from mediastinal nodes is a poor prognostic factor, some
studies have failed to demonstrate a survival disadvantage
[23], raising the possibility that this opinion is probably based
on assumption rather than on hard data, especially since
such spread may render the disease unresectable, rendering
information incomplete.
There has been considerably more debate regarding the
significance of micrometastatic disease in lymph nodes in pa-
tients with surgically resected NSCLC. The fact that a propor-
tion of patients with pStage I (N0) disease relapse and die of
tumour recurrence fuels a presumption of undetected micro-
metastatic disease at the time of surgery. Micrometastatic
disease has no clear definition in the context of lung cancer,
unlike in some other tumours such as breast cancer where
nodal tumour deposits of <2 mm are regarded as micrometas-
tases. Metastatic disease comprising only a few tumour cells
may not be apparent on the standard haematoxylin-and-eo-
sin-(H&E-)stained sections but could be detected on immuno-
histochemistry (IHC) [24]. Various strategies have been
employed to detect micrometastases, usually involving
immunohistochemistry with or without multiple step-sec-
tioning of lymph nodes [25,26]. Most immunohistochemistry
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Ber-EP4 proteins have also been sought [24]. More recently,
studies have utilised reverse transcription polymerase chain
reactions (RT-PCRs) for a variety of mRNA transcripts of
numerous genes, including mucin1, carcinoembryonic antigen
(CEA), p53, KRAS, FHIT, CDKN2A, survivin and livin [24,27,28].
These markers are presumed to be sufficiently specific and
sensitive to detect metastases of any size.
The outcome of these studies will depend on the adequacy
of the ‘standard’ H&E-based initial assessment which deter-
mined N0 status. None of the IHC markers used is specific
for tumour cells, and benign intra-nodal inclusions present
the risk of a false-positive test. The same lack of specificity
applies to most (possibly all) of the mRNA-based studies,
although more recent work has used markers which are more
specific [27]. Other issues with PCR studies include the
following:
• The presence of mRNA does not necessarily mean that
tumour cells are present, only that macromolecules have
been detected.
• Studies have been based upon the homogenisation and
mRNA extraction from fresh/frozen lymph nodes; whilst
other nodes from the same location have been deemed
negative for metastatses, it is an open question as to
whether those homogenised nodes would have been his-
tologically negative if examined in that way.
• There are practical implications in basing a routine test on
fresh, frozen material; however, mRNA from formalin-
fixed, paraffin-embedded tissue can be obtained and
amplified.
Whatever the pros and cons of the technical approach, it is
the outcome that ultimately matters. Can these techniques
upstage – in a clinically significant way – patients otherwise
regarded as having pN0 disease? Such studies are prone to
reporting bias, with several using a range of approaches
‘upstaging’ 20–30% of patients who were considered to be
pN0. It has been suggested that upstaging to pN1 may not
be clinically significant, unlike upstaging to pN2 [25]. A very
detailed original study of over 4000 lymph nodes from 266
Stage I resections, plus a meta-analysis of published work
up to 2008, demonstrated that identified micrometastatic dis-
ease did not significantly decrease postoperative survival [29].
Subsequent publications, however, based upon mRNA PCR,
continue to report significantly poorer postoperative survival
in patients who are pN0 by histological examination but
molecularly N1 or 2 on those nodes examined by PCRTable 2 – Five-year survivals (5YS) in resected non-small-cell ca
Squamous-cell
carcinoma (%)
Pfannschmidt et al., 2007 [35] n = 2376 cases 53.6
Asamura et al., 2008 [36] n = 13,010 cases 52.5
Chansky et al., 2009 [12] n = 9137 cases 43
a These cases would include adenocarcinoma in situ (AIS).
b This is the 5YS for adenocarcinomas excluding those diagnosed as ‘BAC
confounding factors, comparison between cell types within studies are pr[27,28,30]. Notwithstanding the many technical issues around
this approach to detect metastatic disease, and the biological
significance of the findings, there is still a lack of trial evi-
dence that patients would benefit from adjuvant therapy
based upon a molecular upstaging of their tumour.
1.3. Bronchial resection margins
The status of the bronchial resection margin assessed in the
resected specimen has been a matter of some controversy,
and it is difficult to analyse due to limited and heterogeneous
data. The presence of macroscopic disease at the resection
margin (R2) is a poor prognostic factor [31]. R1 disease is also
a poor prognostic factor although there are variables which
need to be considered: the presence of extrachondral disease
at the margin, or lymphangitis carcinomatosa, seems to be
particularly poor prognostic factors, as both are associated
with N2 disease [32–34]. Invasive disease within the mucosa
also determines an R1 resection but may indicate a slightly
smaller risk of recurrence, especially in the context of Stage
I/II disease [32,34]. The significance of carcinoma in situ at
the bronchial resection margin is less clear [33,34]. Unless
the disease is extensive and involving bronchial glands as
well as the mucosal surface [33], there may be insufficient risk
of recurrence to warrant any further therapy [32,34].
2. Tumour histology
Although there is an extensive literature on the subject of tu-
mour histology and prognosis, some studies lack statistical
power, and it is difficult to determine whether any factor is
significant in multivariate analysis, especially in controlling
for Stage and rare tumour types. The use of neo-adjuvant or
adjuvant therapy may also bias the outcomes of analyses.
2.1. Squamous versus adenocarcinoma
Is there a significant difference in postoperative survival be-
tween squamous-cell carcinoma and adenocarcinoma when
controlling for Stage? Even this simple question provides is-
sues to debate, but the probable answer is either ‘very little’
or ‘no difference’ (Table 2). A large German series of 2376
cases found squamous-cell carcinoma patients had a better
5-year survival (5YS) than adenocarcinoma: 53.6% compared
with 48.2% [35]. A Japanese Lung Cancer Registry study of
13,010 cases found the opposite: 5YS for squamous carcino-
mas was surprisingly similar to that of the German study at
52.5%, but the 5YS for all adenocarcinomas was significantlyrcinoma subtypes (all resected stages).
Adenocarcinoma
(%)
Large-cell
carcinoma
Adenosquamous
carcinoma
48.2 45.8 –
67.3a 45.5 42.1
44b 41 29
’(see text). Given variations in stage distribution and other potential
obably more meaningful than those between studies.
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is the inclusion of significant numbers of cases of adenocarci-
noma in situ or minimally invasive adenocarcinoma in this
cohort (see Types of adenocarcinoma, below). These lesions are
more common in Japanese studies, and until the publication
of the new IASLC/ERS/ATS recommendations of adenocarci-
noma classification [37] these cases were often classified as
well-differentiated adenocarcinoma. It is now known that
they pose no metastatic risk and show 100% 5YS. In the IASLC
staging study cohort of 9137 cases, cases reported as ‘bronchi-
oloalveolar carcinoma’ (BAC) were separated out from other
adenocarcinomas and showed a 5YS of only 61%. The low fig-
ure suggests that this was still a pathologically heterogeneous
group, comprising true ‘BAC’ i.e. adenocarcinomas in situ,
and other invasive adenocarcinomas incorrectly classified as
BAC (see below). The effect of this separation was to leave
the non-BAC adenocarcinoma group with a 5YS of 44%, not
significantly different from the 43% 5YS for squamous-cell
carcinomas [12].
2.2. Types of squamous-cell carcinoma
The WHO classification of lung tumours [38] describes a pap-
illary variant of squamous-cell carcinoma that generally has a
good prognosis, probably because it demonstrates limited
invasion and tends to be of low stage. Similarly, so-called
‘creeping’ squamous-cell carcinoma [39], an invasive tumour
confined to the mucosa, demonstrates relatively indolent
biology and a relatively good prognosis. Peripherally located
squamous-cell carcinoma, arising from third-order or greater
bronchi, may be increasing in prevalence. The growth pattern
of these tumours may be infiltrative and destructive or non-
infiltrative with preservation of lung architecture, the so-
called alveolar filling growth pattern [40–42]. When this latter
pattern is prominent, tumours tend to be of lower stage, show
less vascular invasion (see below), and patients survive for
longer [40–42]. Despite the relatively poor prognosis demon-
strated by basaloid carcinoma (see Other histological types, be-
low), the basaloid variant of squamous-cell carcinoma has
been shown to be no more aggressive than poorly differenti-
ated squamous-cell carcinoma [43,44].
2.3. Types of adenocarcinoma
The proposed changes in adenocarcinoma reporting and clas-
sification for surgically resected cases – authored by a multi-
disciplinary group of experts representing the IASLC, the
European Respiratory Society (ERS) and the American Tho-
racic Society (ATS) – are largely based upon significant differ-
ences in prognosis demonstrated by different histological
subtypes of adenocarcinoma [37]. This work acknowledged
published descriptions of bronchioloalveolar carcinoma
(BAC) and how that diagnosis is often associated with a better
postoperative outcome. It also noted that there was enor-
mous variation in type of tumour classified as BAC, in many
instances that were clearly not BAC as defined in the 1999
and 2004 WHO classification. This led to the strong recom-
mendation that the use of the term BAC be discontinued; that
cases fulfilling criteria for BAC (small, localised lesions lack-
ing invasion and showing only lepidic growth around alveolarwalls) be reclassified as adenocarcinoma in situ (AIS), since
such lesions pose no metastatic risk and have 100% 5YS
[45], and that other lesions with evidence of invasion be clas-
sified as invasive adenocarcinoma, even if there is widespread
lepidic pattern disease.
In resected invasive adenocarcinomas, the degree of inva-
sion in a lesion which is otherwise AIS with a lepidic growth
pattern may be very limited in extent. Assuming that some
(most?) adenocarcinomas arising in the lung develop in this
way, such lesions would be expected. If the focus of invasion
in such a lesion is <5 mm in maximum diameter, there is still
no metastatic risk and patients have 100% 5YS [46,47]. Such
lesions are classified as minimally invasive adenocarcinomas
(MIAs). If the focus of invasion, characterised by one or more
of the other four invasive adenocarcinoma patterns (acinar,
papillary, micropapillary, solid with mucin), is >5 mm across,
the resected tumour is classified as invasive adenocarcinoma
and a qualifier should be added to the classification when the
report is issued by the pathologist, indicating which pattern
of disease is the predominant one. This is also strongly rec-
ommended because of the notable prognostic effect: several
studies have shown that resected adenocarcinomas with a
predominantly lepidic pattern have a relatively good progno-
sis, independent of stage. Conversely, cases which are pre-
dominantly micropapillary or solid in pattern have a
relatively poor prognosis [48–52]. Some studies show poor
prognosis for papillary predominant disease [50], whilst oth-
ers do not [48], possibly due to differences in interpretation
of the papillary pattern. Although these patterns can be reli-
ably and consistently identified, some are more difficult than
others, notably papillary patterns [53].
2.4. Multiple tumours
The presence of multiple synchronous carcinomas was tradi-
tionally considered a poor prognostic factor for both squa-
mous-cell carcinomas and adenocarcinomas [54],
presumably reflecting intrapulmonary metastases in many
cases. A better understanding of carcinogenesis in these
two distinct tumour types, and recognition that multiple syn-
chronous primary tumours – especially adenocarcinoma – are
not uncommon, has modified this view. Multifocal disease
undoubtedly reflects a biologically heterogeneous group of
cases, making generalisations unhelpful. Unusual cases of
mucinous or non-mucinous multifocal, predominantly lepi-
dic pattern adenocarcinomas (the mucinous form now re-
ferred to as mucinous adenocarcinoma) were formerly
considered to be BAC, despite these cases not fulfilling the
post-1999 definition. Although demonstrating relatively indo-
lent growth behaviour, these tumours carry a relatively good
prognosis, with less propensity to spread widely outside the
thorax, although they are invasive and do represent ad-
vanced, potentially fatal disease.
2.5. Other histological types
Large-cell carcinomas and sarcomatoid carcinomas appear to
be aggressive, often large lesions [38]. Whether the associated
poor prognosis is independent of stage is less clear. In the
large studies presented in Table 2, large-cell carcinomas
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comatoid carcinomas are rare lesions which may or may not
demonstrate components of differentiated squamous-cell or
adenocarcinoma. These tumours are renowned for a poor
prognosis and aggressive behaviour, although published ser-
ies of cases are generally small [55–58]. There are two variants
of large-cell carcinoma which are notable for their poor prog-
nosis: basaloid carcinoma and large-cell neuroendocrine car-
cinoma (LCNEC). Case series of basaloid carcinomas are few,
but data suggest an aggressive tumour, often of high stage
at presentation, and a propensity for brain metastases
[59,60]. LCNEC is a high-grade neuroendocrine carcinoma
sharing many epidemiological and genetic features with
small-cell carcinoma. This is a highly invasive tumour type
prone to widespread metastases [61–63].
2.6. Other histological features
Certain histological features, independent of histological tu-
mour type, have been shown to be independent prognostic fac-
tors. Features such as vascular invasion, lymphatic invasion,
pleural invasion, tumour necrosis and poor differentiation have
beenso reported. Thefirst three featuresare intuitive, andrelate
to key factors in the TNM system which correlate with poor
prognosis.Vascular invasionwithin the tumour isa feature con-
sistently associated with early relapse featuring distant meta-
static disease [64]. Lymphatic invasion is associated with
increased risk of lymph-node metastases [65]. The poor prog-
nostic effect of pleural invasion is reflected in this feature,
upstaging tumours in the TNM classification [66]. Tumour
necrosis is usually associatedwith larger tumours, more poorly
differentiated lesions and greater proliferative activity being
indicative of an aggressive phenotype. Poor differentiation has
long been associated with aggressive tumour behaviour and
most of the other features determining higher tumour stage
[38]. Criteria for grading tumours in this way have been poorly
described and undoubtedly inconsistently applied by patholo-
gists. However, there is increasing interest in tumour grading
as an important factor in lung tumour pathology [67].
Tumour cell proliferation deserves particular consider-
ation. High mitotic activity has long been recognised as an
indicator for the presumption of relatively rapid tumour
growth, and high mitotic indices are certainly associated with
poorly differentiated tumours and tumours which have
recognised aggressive biology (small-cell and large-cell neuro-
endocrine carcinomas). It is also a diagnostic defining feature
for carcinoid versus atypical carcinoid tumour, and de facto, of
large-cell neuroendocrine carcinoma with most assessments
made on resected tumour specimens. This differential diag-
nosis carries recognised prognostic significance [38].
There are several problems in relying upon mitotic index
as an indicator of likely tumour growth rate:
• Mitoses may be difficult to recognise on pathological
specimens.
• The mitotic (M) phase of the cell cycle is relatively short so
may poorly reflect overall cell cycle activity.
• Actual tumour growth is dependent on the balance
between cell production and cell loss, the latter being very
difficult to assess in tumours.Proteins expressed during part or all of the cell cycle have
been used as proliferation markers, although strictly speaking
they only indicate cell cycle ‘activity’ and do not provide
unequivocal evidence of cell division. These markers include
proliferating cell nuclear antigen (PCNA), Ki67, a variety of the
minichromosomemaintenance proteins (MCMs) and histone-
H3. MCMs may have an advantage over Ki67 in being evenly
expressed throughout all phases of the cell cycle, whereas
Ki67 accumulates later in G1, persisting through S, M and
G2. PCNA has not shown convincing prognostic significance
in NSCLC [68]. By far the greatest literature has been con-
cerned with Ki67 expression in both early, surgically resected
and advanced NSCLC, mostly as measured by the MIB1 anti-
body [68,69]. Two reviews, including publications up until
2006, described 46 reports of Ki67 as a prognostic factor in
NSCLC [68,69], of which only 19 (41%) show ‘over-expression’
of Ki67 as a poor prognostic marker. Most found no indepen-
dent effect on prognosis.
Actual tumour growth rates may be derived from preoper-
ative imaging measurements and expressed as a volume dou-
bling time (vDT) [70,71]. This parameter has been related to
postoperative survival, some studies demonstrating an asso-
ciation between short vDT and poorer prognosis, although
the relationship is not clear cut [72–74]. vDT is also used as
a factor in predicting malignancy during nodule follow-up, of-
ten in the context of lung cancer screening [74,75].3. Tumour molecular pathology
There is probably more literature on the putative prognostic
effects of molecular markers in lung cancer than exists for
other prognostic features in this disease. This is not surpris-
ing since molecular changes are the fundamental factors
driving each tumour, making it behave in a unique way.
Molecular markers are perceived to be more objective assess-
ments than are some other pathological features. They are
also considered to be more easily measured, numerous and
to possess ‘scientific’ and ‘topical’ cache.
Studies have ranged from single marker investigations to
pan-genomic works using a variety of approaches. Comparing
studies of the more commonly investigated biomarkers is
hampered by enormous heterogeneity of study design, varia-
tion in techniques, case mix and interpretation of data. Con-
tradictory conclusions are frequently drawn, and perhaps
because of this – and despite the enormous amount of data
available – there is not a single molecular prognostic bio-
marker in regular clinical use for managing patients with lung
cancer. A review of the topic in 1995 identified this issue and
proposed trials of biomarkers in selecting patients for adju-
vant therapy on the basis of claimed prognostic significance
[76]. To date, very little progress has been made. It is only re-
cently that mRNA-based gene signatures have been seriously
investigated in this context (see below).‘Single gene’ studies
have tended to use immunohistochemistry (IHC) to identify
the protein product of the gene(s) of interest, although there
are many studies looking at gene mutation, fusion or amplifi-
cation using a variety of techniques. Gene transcription prod-
ucts (mRNA) have also been used, either for specific genes or
using a more global approach using array techniques. Global
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using comparative genomic hybridisation (CGH), are now fre-
quent, although they have been less often studied from a
prognostic perspective.
One of the most critical issues regarding tumour biomark-
ers concerns methodology. Techniques for carrying out the
test, the reagents used, methods used to score/quantify the
result, the analysis and interpretation of the results are all
critical yet prone to variability and error. Some are more sub-
jective than others; many are simple and readily available,
others are complex, expensive and less accessible. Complex-
ity does not guarantee accuracy, greater reliability or rele-
vance. In terms of biomarker testing of tumour samples, the
handling and processing of the tissues prior to testing are of
critical importance yet difficult to standardise, but these fac-
tors are often ignored or overlooked [77,78].
A comprehensive review of prognostic biomarkers in lung
cancer is beyond the scope of this article, but there follows a
selective commentary on some important issues.
3.1. Immunohistochemistry
Following others’ methodology in reviewing the literature
[79], in 2006 Zhu and colleagues published an excellent and
extensive review of 462 original papers and 12 reviews on
immunohistochemical markers of prognosis in NSCLC pub-
lished between 1987 and 2005 [68]. These studies focused
mainly on resected NSCLC. Their data were helpfully grouped
according to Hanahan and Weinberg’s original six hallmarks
of cancer [80] and accounted for 50 different markers. They
identified five markers (EGFR, HER2, Ki67, p53 and bcl2) which
had been extensively studied and were the focus of meta-
analyses. For Ki67 and p53, higher levels of expression
showed a weak but significant poor prognostic effect whilst
high bcl2 showed a weak but significant poor prognostic ef-
fect. The authors suggested that ‘over-expression’ of cyclinE
and VEGF, and p16, p27 and beta-catenin, were ‘promising’
as poor and good prognostic factors respectively. They also
highlighted hepatocyte growth factor (HGF) and MET as
potentially important, given in vitro data. Only MET has sub-
sequently emerged as being clinically relevant due to its pro-
viding a therapeutic target and predictive factor rather than
being a poor prognostic factor [81]. One of the most telling as-
pects in the review of Zhu et al. is that for almost every mar-
ker that is the subject of more than two publications, the
prognostic effect claimed by some is absent in others. On oc-
casion there are studies claiming good, poor and no prognos-
tic effect for the same marker [68]. The authors highlight the
differences in use of antibodies and definitions of over-
expression as the probable explanation for such variation in
outcome and emphasise the need for a consistent, planned
approach to execution of such studies.
A more recent review of 111 reports took a very similar ap-
proach to that of Zhu et al. but concentrated on biomarkers
relating to three of the six hallmarks of cancer: cell cycle
activity, apoptosis and angiogenesis [82]. The authors’ conclu-
sions were similar, in that cyclin E, VEGF, p27 and p16 showed
some prognostic effect, although bcl2 did not. Cyclin B1, p21,
survivin and collagen VIII were also identified to have suffi-
cient potential as independent predictors of patient outcome.The potential for use of combined panels of markers as prog-
nostic predictors was also emphasised in this review.
The plethora of literature and inconsistency of data were
highlighted in a further review [83] which also suggested that,
given the molecular heterogeneity of lung cancer, it was unli-
kely that a single marker would emerge as universally useful.
Essentially this is true, although a decision to treat or not
could be based upon a simple binary evaluation of a reliable
marker at a certain threshold, including patients with no
expression. Such a marker has yet to emerge. Meta-analyses
have suggested that TTF1 is a good prognostic factor in re-
sected adenocarcinoma [84], whilst COX2 may be a weak,
poor prognostic factor in stage I disease [85].
The determination of the best threshold (cut-off) for a
quantifiable biomarker is also frequently unexplained or
poorly executed. Simplistic approaches such as present/ab-
sent or above/below a median may ignore the biology of the
system under study and will fail if the effect sought varies
around a point elsewhere in the range. It is much better to
use a statistical approach to determine the most effective
threshold [86]. This is just one of the methodological factors
which requires to be standardised if real progress is to be
made with tumour biomarker testing and application [68,87].
3.2. Gene mutation and copy number
Gene mutations potentially have the same pitfalls as single
IHC biomarkers, in terms of being ubiquitous and yet ade-
quately discriminating in order to be clinically useful. Unlike
with IHC biomarkers, where NSCLC subtype has largely been
ignored, mutation studies have demonstrated prognostic ef-
fects for some mutations which are mostly found in lung
adenocarcinomas.
TP53 mutations are the commonest mutation found in
lung cancer and do appear to be associated with poor progno-
sis, but they are associated with positive smoking status,
squamous cell as opposed to adenocarcinoma histology, male
gender, poor tumour differentiation and higher stage disease
at presentation [88,89]. Analysis of the effect of the mutation,
as opposed to other associated factors, is therefore challeng-
ing. In multivariate analyses, TP53 mutations have not been
reliably independent prognostic factors in two surgical series
[88,90], despite being associated with shorter postoperative
survival in one of these studies [88].
Mutations in codons 12, 13 and 61 of KRAS are relatively
frequent in lung adenocarcinomas, being found in up to
40% of European and North American cases but in around
10% of Japanese cases [88,91,92]. Individual studies and
meta-analysis have demonstrated a poor prognostic effect
of KRAS mutation [88,90,91,93–95] but some of these associ-
ations were rather weak and have not stood up to multivar-
iate analysis [88,90,94,96]. KRAS mutation is associated with
positive smoking status, poor tumour differentiation and
higher stage, again probably confounding the prognostic ef-
fect. The presence of increased gene copy number as well
as mutation in KRAS has been associated with poor progno-
sis [95].
Mutations on the tyrosine kinase domain of EGFR occur in
around 50% of adenocarcinomas in East Asian patients and
around 15–20% of European/North American patients [92].
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smoking, are generally perceived to be a good prognostic fac-
tor. Although some studies have shown a good prognostic ef-
fect in surgically resected adenocarcinomas [97], there are
many studies in which this effect does not survive multivari-
ate analysis [88,90,94,96,98,99]. EGFRmutations are associated
with lower stage disease [98], well-differentiated adenocarci-
nomas [88] and tumourswith a predominantly lepidic compo-
nent [100], all factors known to carry a good prognosis. In
adenocarcinomas, high copy number of EGFR was reported
as a good prognostic factor in one study [94] but another
found no effect [99]. In studies looking at ‘NSCLC’, EGFR poly-
somy/amplification has been reported as a poor prognostic
factor overall [101,102], or in squamous-cell carcinoma but
not in adenocarcinoma [103]. The overall impression is that
whilst EGFRmutations are associated with a better prognosis,
this effect is not independent of the other good prognostic
factors with which this mutation is associated.
To expand on the statement regarding HGF as a poor prog-
nostic factor, MET is the HGF receptor and increase in MET
gene copy number is associated with poorer survival through
more aggressive tumour biology, higher tumour stage and
histological grade [81,104,105]. ALK fusion genes and BRAF
mutations are targetable oncogenic drivers in advanced ade-
nocarcinomas. ALK fusion may be a good prognostic factor
in surgically resected and advanced-stage adenocarcinomas
[106–108], even although ALK fusion is associated with solid
and cribriform adenocarcinomas with signet ring cells,
aggressive histological features [37,108]. ROS1 and RET fusion
both also appear to be good prognostic factors [108]. This may
be because tumours bearing these various gene fusions are
not associated with tobacco carcinogenesis. BRAF mutations
are associated with micropapillary adenocarcinoma histol-
ogy, a poor prognostic factor [109].
3.3. Pan-genomic studies
Global chromosomal disarray, often reflected in tumour-cell
nuclear pleomorphism, has long been associated with aggres-
sive tumour behaviour. More extensive genetic gains and
losses shown by comparative genomic hybridisation (CGH)
are associated with higher tumour stage, poor differentiation
and tumour progression [110–113], and early relapse of re-
sected adenocarcinoma [114].
Oligonucleotide and cDNA expression microarrays can be
used to determine the expression of thousands of genes from
mRNA extracted from resected tumour samples [115]. This
technology has been used extensively to characterise resected
lung carcinomas. The clustering of tumours into different
groups that share patterns of gene expression has led to sub-
divisions and molecular classifications of lung adenocarcino-
mas in particular [116–120]. These subdivisions have been
associated with differential patient survival, but a closer
examination of the categories with better or worse prognosis
suggests many of these molecular subdivisions are recapitu-
lating histological factors already recognised as prognostic
[37]: well and poorly differentiated tumours, or lepidic pre-
dominant tumours [119–121].
There is also an extensive literature investigating the po-
tential for mRNA-based gene expression profiles to predictoverall survival in surgically resected lung cancer [122–129],
disease recurrence in stage I patients [130–133] and lymph-
node metastatic disease [134–136]. Panels (signatures) ranging
from 2 to 8644 genes were identified for squamous–cell carci-
noma, adenocarcinoma or all histological types, but it is strik-
ing that there is almost no overlap in the genes identified
between studies. Also, depending on the statistical methods
applied, it is possible to generate different predictive signa-
tures from the same data set [137]. The extent to which inves-
tigators undertook validation of their signature is variable.
One large study did attempt multi-institutional validation
but essentially failed to produce a robust, consistent signa-
ture, although the molecular data did appear to enhance the
prognostic value of the clinical data available [138]. One
PCR-based study did validate a ten-gene prognostic signature
for Stage I adenocarcinoma between a European and a North
American centre with 75% accuracy [139], whilst another val-
idated a 14-gene expression assay in two North American and
one Chinese institution [140], generating three risk groups in
resected stage I–III non-squamous carcinomas ranging from
74.1% to 44.6% 5YS. There is no overlap between the 10- and
14-gene sets used by these groups, and neither of these stud-
ies included squamous-cell carcinomas.
The appeal of such positive signatures is obvious, but there
are many similar and all claim more or less the same prog-
nostic power. None of these has been prospectively tested
as a means to select patients for adjuvant therapy, but trials
are ongoing and the outcomes are awaited with interest.
Whether any of these trials will risk (allow?), in case of adeno-
carcinomas, any comparison with the prognostic stratifica-
tion by histology [48–52] remains to be seen.
Other molecular signatures have been related to progno-
sis. In studies of squamous-cell carcinoma, a panel of five
microRNAs’ (miRNA) expression has been related to increased
mortality risk in squamous-cell carcinomas [141], whilst miR-
NA expression was found to be superior to an mRNA signa-
ture in predicting overall survival [142]. Lu et al. reported
two prognostic miRNA signatures in resected stage I lung can-
cers, one for all NSCLC types, and a different one for adeno-
carcinoma only [143]. Promoter methylation of the P16 gene
as a mechanism of gene silencing has been suggested as a
poor prognostic factor in NSCLC in one meta-analysis [144].
In a case–control study of resected Stage I NSCLC, promoter
methylation of P16, CDH13, RASSF1A and APC was associated
with early relapse due to tumour recurrence, an effect inde-
pendent of stage, tumour histology and patient characteris-
tics [145].
There is no specific conclusion to be reached with regard
to resected NSCLC genetics and prognosis. It stands to reason
that more aggressive tumour behaviour, with the propensity
for postoperative disease relapse, is likely to be driven by ge-
netic changes in tumours. Given the diversity of NSCLC, it
seems unlikely that any such ‘genetic signature’ will com-
prise only one or two altered genes. Combinations of genetic
alterations making an individual tumour more aggressive are
highly likely to vary from case to case, depending upon histol-
ogy, aetiology and other factors. It remains to be seen
whether clinically useful prognostic genetic signatures can
be identified, and what forms of genetic alteration these will
be.
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The importance of the tumour immune response in tumour
progression has been recognised by the inclusion of both tu-
mour-promoting inflammation and mechanisms to avoid im-
mune destruction in the next generation of hallmarks of
cancer [146].
Chronic inflammatory cell infiltrates (lymphocytes, plas-
ma cells and macrophages) are common in resected NSCLC
but global histological assessment of these infiltrates has
failed to show prognostic significance [147]. If, however, the
microlocation (stroma versus amongst the tumour cells) and
cell content of these infiltrates are taken into account, there
is an effect on prognostics in resected NSCLC. Intra-tumoural
infiltrates rich in CD4+ lymphocytes and S100+ Langerhans
cells are associated with better postoperative survival [147].
Uncommon examples of resected NSCLC showing marked
immune cell destruction reminiscent of immunological
regression seen in renal and skin cancers have been reported
[148]. These cases had a superior postoperative survival,
showed evidence of radiological shrinkage prior to resection,
and were characterised by infiltrates rich in Langerhans cells,
CD4+ and CD57+ lymphocytes and macrophages.
More recent studies have been better able to characterise
the nature of intra-tumoural immune-cell infiltrates, and
there are several reviews and many reports of tumour-infil-
trating lymphocytes (TIL – B cells, CD4+ and CD8+ T cells, nat-
ural killer cells), macrophages, plasma cells and others,
generally demonstrating that immunological reactions seem
to indicate a more favourable prognosis in resected NSCLC
[149–152]. There are reports, however, of certain TIL cell types,
such as FoxP3+ T cells and macrophages over-expressing IL10
or TREM-1, which seem to be pro-tumourigenic and associ-
ated with shorter survival [150]. Prognostic immune gene pro-
files have also been derived from tumour mRNA extracts
[150], supporting the histological data on intra-tumoural im-
mune-cell infiltrates. In an interesting evolution of this argu-
ment, mRNA gene signatures derived from circulating blood
mononuclear cells have been shown to be prognostic in
NSCLC patients [153,154].5. Tumour metabolism
Tumour metabolism, as assessed by 18F-fluorodeoxyglucose
positron emission tomography (FDG-PET), has been shown
to correlate with tumour stage, lymph-node involvement
and postoperative survival [155]. Higher PET positivity
(SUVmax) indicates higher tumour metabolism and is a poor
prognostic factor which also correlates with central tumour
location, squamous-cell rather than adenocarcinoma sub-
type, poor tumour differentiation, larger tumour size, pleural
invasion, lymph-node metastases and higher stage. SUVmax
has been shown to be an independent prognostic variable in
resected NSCLC in multivariate analysis [156–158]. In resected
stage I adenocarcinomas, patients at high risk of disease
recurrence could be identified on the basis of lymphovascular
invasion and by SUVmax [158]. High SUVmax also correlates
with high tumour-cell density and high cell cycle activity
(Ki67 assay) [157]. In a meta-analysis, 11 out of 13 studiesconcluded that high SUVmax was a poor prognostic factor in
resected NSCLC [159]. The threshold SUVmax described by var-
ious authors separating good from poor prognostic cases is
very variable, probably the result of case and histological
mix, but also variations in scanners used.
6. Conclusion
There is a clinical need for better prognostic markers which
more effectively identify patients with resected NSCLC who
are at most risk of disease relapse/recurrence, in the hope
that more efficient selection will lead to better outcomes from
adjuvant therapy. Many studies have identified prognostic
factors relating to the tumour type, extent, histopathological
features, individual molecular characteristics and more glo-
bal, multiplex genetic assessments as well as factors related
to tumour immune responses and metabolism. Of these, only
tumour stage is currently used in clinical decision-making,
but the relatively poor survival gains from adjuvant therapy
suggest that this approach to patient selection could be im-
proved upon. Given the multiplicity of NSCLC types, frequent
intra-tumoural heterogeneity and the biological differences
between the two major subtypes of squamous-cell carcinoma
and adenocarcinoma, it is unlikely that a single histological
feature or molecular change will provide the required finer
discrimination. It is also likely that any solution will differ be-
tween squamous-cell carcinoma and adenocarcinoma. More
complex, multiplex assessments of genetic change may prove
more effective, but we should not ignore histopathological
classification which, ultimately, is a morphological reflection
of the myriad genetic changes present in the lesion. Prospec-
tive trials to select adjuvant therapy based upon proven prog-
nostic factors are needed, but these should embrace validated
histopathological assessment as well as molecular profiles.
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